Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Artemether-Lumefantrine vs ETOMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Treatment of uncomplicated malaria due to Plasmodium falciparum,Treatment of chloroquine-resistant malaria
Induction of general anesthesia,Procedural sedation (off-label),Rapid sequence intubation (off-label)
Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
Artemether: terminal elimination half-life approximately 1–2 hours. Dihydroartemisinin: approximately 1–2 hours. Lumefantrine: terminal elimination half-life 4–5 days (range 2–6 days) in patients with uncomplicated malaria; prolonged half-life contributes to post-treatment prophylaxis but may lead to accumulation with repeated dosing.
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Artemether is metabolized by CYP3A4 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Etomidate is extensively metabolized in the liver via hydrolysis of the ester side chain by hepatic esterases to its principal metabolite, etomidate carboxylic acid. A minor metabolite is formed via N-demethylation. Metabolites are inactive.
Primarily fecal (biliary) elimination of unchanged drug and metabolites; renal excretion is negligible (<1% for artemether and <0.1% for lumefantrine). Artemether is extensively metabolized by CYP3A4/5 to dihydroartemisinin, which is further glucuronidated and excreted in bile. Lumefantrine is metabolized by CYP3A4 to desbutyl-lumefantrine; both parent and metabolite are eliminated via feces.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Artemether: 95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Dihydroartemisinin: 93% bound. Lumefantrine: >99% bound to high-density lipoproteins (HDL) and, to a lesser extent, to albumin and α1-acid glycoprotein.
76% bound to albumin.
Artemether: Vd approximately 2–5 L/kg, indicating extensive tissue distribution. Dihydroartemisinin: Vd 0.5–1.5 L/kg. Lumefantrine: Vd extremely large, ranging from 10–30 L/kg (reported up to 31 L/kg), reflecting extensive tissue binding and accumulation in erythrocytes and organs (liver, lung, kidney).
Vd: 2.5–4.5 L/kg (large, indicating extensive tissue uptake).
Oral bioavailability: Artemether is 30–40% due to extensive first-pass metabolism by CYP3A4/5 to dihydroartemisinin, which has 80% oral bioavailability. Lumefantrine has highly variable and food-dependent bioavailability; absorption increases 2–16 fold when taken with a high-fat meal. Bioavailability is approximately 5–10% in the fasted state and up to 85% when administered with fat-containing food. The combination is formulated to enhance lumefantrine absorption with a fixed ratio of artemether:lumefantrine 1:6.
IV: 100% (only route used clinically).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
No dose adjustment required for renal impairment. Hemodialysis does not alter dosing. Use caution in severe renal failure due to propylene glycol vehicle if prolonged infusion.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); avoid use.
No specific adjustment for Child-Pugh class. However, prolonged effect may occur in severe hepatic impairment; reduce induction dose by 50% and titrate to effect.
Weight-based dosing: 5-<15 kg: 1 tablet per dose; 15-<25 kg: 2 tablets per dose; 25-<35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer at 0, 8, 24, 36, 48, and 60 hours. Crush tablets if needed for children <5 kg.
Induction: 0.2–0.6 mg/kg IV (max 40 mg). Age >10 years: use adult dosing. Neonates and infants: reduce dose to 0.3 mg/kg due to higher volume of distribution.
No specific dose adjustment required. Monitor for QT prolongation and electrolyte disturbances due to potential age-related decline in cardiac conduction.
Induction: 0.15–0.3 mg/kg IV (50% reduction of adult dose) due to decreased clearance and increased sensitivity. Use lower end of dosing range.
None
Etomidate has been associated with mortality in children. It should not be used in children younger than 6 months of age. (This warning is included in the prescribing information based on FDA labeling; specific text may vary.)
QT interval prolongation,Arrhythmias,Recrudescence of infection,Hypersensitivity reactions,Use in hepatic impairment
Inhibition of adrenal steroidogenesis (adrenal suppression) due to blockade of 11-beta-hydroxylase, leading to decreased cortisol and aldosterone production; may persist for 12-24 hours after single dose,Myoclonic movements during induction (involuntary muscle contractions),Hypotension and bradycardia (less common than with other induction agents),Venous irritation and pain on injection (may be reduced by using larger veins)
Hypersensitivity to artemether or lumefantrine,Severe malaria,Pregnancy (first trimester) unless no other option
Hypersensitivity to etomidate,Patients with acute porphyria (may be porphyrinogenic)
High-fat meal increases absorption; grapefruit juice may increase lumefantrine levels; avoid concurrent use.
No specific food interactions are known. Etomidate is administered intravenously and does not have oral bioavailability. However, concurrent use of drugs that affect CYP3A4 (e.g., grapefruit juice) is not clinically significant due to IV route.
FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and third trimester: limited human data but appears safe; no increased risk of congenital malformations reported. Use only if benefit outweighs risk.
Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a slightly increased risk of congenital malformations, but data are limited. Risks to the fetus should be weighed against the benefits of maternal anesthesia. The drug is not recommended during pregnancy unless clearly needed, especially during organogenesis. In the second and third trimesters, etomidate may cause fetal central nervous system depression and respiratory depression if used near term.
Both artemether and lumefantrine are excreted in breast milk in low amounts. M/P ratio: artemether ~0.3, lumefantrine ~0.5. Considered compatible with breastfeeding; no adverse effects observed in infants. Use caution if infant has G6PD deficiency due to theoretical risk of hemolysis.
It is unknown whether etomidate is excreted in human breast milk. The molecular weight (244.3) suggests potential excretion into milk. The milk-to-plasma ratio (M/P) has not been determined. Due to the short half-life (2–5 hours) and use as a single induction dose, transfer to the infant is likely minimal. However, caution is advised. The American Academy of Pediatrics classifies etomidate as 'compatible' with breastfeeding after a single dose, but data are insufficient for repeated or prolonged use. Infants should be monitored for sedation and respiratory depression.
No dose adjustment required for uncomplicated malaria in second and third trimester. First trimester: avoid unless no alternative; use same weight-based dosing. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) do not mandate dose changes; standard 6-dose regimen over 3 days is recommended.
No specific dose adjustments are recommended for etomidate during pregnancy, but the dose should be individualized to achieve the desired level of anesthesia with the lowest effective dose. Physiologic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect pharmacokinetics, but etomidate is rapidly redistributed and has a short duration of action. The standard induction dose of 0.2–0.6 mg/kg IV is used. Close monitoring of maternal and fetal status is advised. In cesarean section, lower doses may be considered to reduce fetal depression.
Monitor ECG for QTc prolongation; administer with fatty food to enhance absorption; avoid in patients with severe hepatic impairment; pregnancy category C; caution with CYP3A4 inhibitors or inducers.
Etomidate is an induction agent of choice in hemodynamically unstable patients due to minimal cardiovascular depression. Adrenal suppression occurs even after a single dose, manifesting as decreased cortisol and aldosterone synthesis via 11β-hydroxylase inhibition. Administer slowly over 30-60 seconds to reduce myoclonus and pain on injection. Use a lower dose (0.2-0.3 mg/kg IV) in elderly or debilitated patients. Etomidate is not recommended for rapid sequence intubation in septic shock due to risk of adrenal insufficiency; consider ketamine as alternative. Prolonged infusion is not advised due to propylene glycol vehicle and adrenal suppression.
Take with a high-fat meal or whole milk to improve absorption.,Complete the full 3-day course even if symptoms improve.,Seek medical attention for signs of severe malaria (e.g., altered consciousness, difficulty breathing).,Avoid grapefruit juice during treatment.,Use effective contraception if of childbearing potential.
You may experience brief involuntary muscle movements during injection, which are usually harmless.,Tell your doctor if you have adrenal gland problems or are taking corticosteroids.,This drug may cause a temporary decrease in your body's ability to produce stress hormones.,Avoid driving or operating machinery until the effects of the medication have completely worn off.,Report any severe pain at the injection site or unusual weakness after the procedure.
"Anagrelide, a phosphodiesterase 3 (PDE3) inhibitor used for thrombocythemia, and artemether, an antimalarial artemisinin derivative, both prolong the QT interval by inhibiting cardiac potassium channels (specifically IKr). Concurrent use may result in additive QTc prolongation, increasing the risk of Torsade de Pointes and other ventricular arrhythmias. This risk is particularly relevant in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"Acepromazine, a phenothiazine antipsychotic/antiemetic, inhibits cytochrome P450 3A4 (CYP3A4), the primary enzyme responsible for metabolizing the antimalarial artemether. Concomitant administration can lead to significantly reduced clearance of artemether, elevating its plasma concentrations. This may increase the risk of dose-dependent toxicities, including neurotoxicity (e.g., ataxia, seizures) and cardiotoxicity (e.g., QT prolongation)."
"Concomitant administration of thioridazine, a potent CYP2D6 inhibitor, with artemether, a substrate of CYP2D6, can significantly increase the serum concentration of artemether. This elevation may potentiate the antimalarial effect but also heightens the risk of artemether-related adverse effects such as QT prolongation and neurotoxicity. Clinically, this interaction warrants caution due to potential cardiotoxicity and altered drug exposure."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"The combination of Promazine, a phenothiazine antipsychotic with strong alpha-adrenergic blocking activity, and Etomidate, a non-barbiturate hypnotic used for induction of anesthesia, can lead to an increased risk of hypotension due to additive vasodilatory effects. Promazine's alpha-1 receptor antagonism impairs compensatory vasoconstriction, while Etomidate suppresses adrenal cortisol synthesis, potentially blunting the stress response and further reducing hemodynamic stability. Clinically, this interaction may result in profound hypotension, especially in hypovolemic or elderly patients, requiring careful dose titration and monitoring."
"The coadministration of oxazepam, a benzodiazepine that enhances GABA-A receptor activity, with etomidate, a non-barbiturate anesthetic that also potentiates GABA-A receptor function, results in additive central nervous system (CNS) depression. This synergistic interaction can lead to excessive sedation, respiratory depression, hypotension, and prolonged recovery from anesthesia. Patients are at increased risk of apnea, hypoxia, and hemodynamic instability, particularly during induction and maintenance of anesthesia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Artemether-Lumefantrine vs ETOMIDATE, answered by our medical review team.
Artemether-Lumefantrine is a Antimalarial that works by Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.. ETOMIDATE is a General Anesthetic that works by Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Artemether-Lumefantrine and ETOMIDATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Artemether-Lumefantrine is: Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.. The standard adult dose of ETOMIDATE is: Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Artemether-Lumefantrine and ETOMIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Artemether-Lumefantrine is classified as Category C. FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and thir. ETOMIDATE is classified as Category C. Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-co. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.